ReadoutJul 14, 2026
Clinical data — Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies▸
medium impact
ApprovalJul 13, 2026
FDA approval — Moderna, Takeda and Capricor on the verge of notching big drug approvals▸
high impact
DealJun 26, 2026
Deal — S&P 500 ends lower; chips tumble and Moderna rallies▸
medium impact
AdComJun 24, 2026
FDA advisory — How Unanimous FDA Panel Support For mRNA Flu Shot At Moderna (MRNA) Has Changed Its Investment Story▸
high impact
AdComJun 22, 2026
FDA advisory — Moderna’s mRNA flu vaccine passes FDA AdCom, review underway▸
high impact
AdComJun 19, 2026
FDA advisory — Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0▸
high impact
AdComJun 18, 2026
FDA advisory — MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine▸
high impact
AdComJun 17, 2026
FDA advisory — FDA Panel Set To Debate Moderna Flu Shot▸
high impact
AdComJun 16, 2026
FDA advisory — Why Is Moderna (MRNA) Stock Soaring Today▸
high impact
AdComMay 26, 2026
FDA advisory — Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine▸
high impact
EarningsMay 01, 2026
Q1 2026 report+7.5%positive
EarningsFeb 13, 2026
FY 2025 report+17.7%positive
EarningsJan 12, 2026
FY 2025 report+16.3%positive
EarningsNov 06, 2025
Q3 2025 report+8.5%positive
EarningsAug 01, 2025
Q2 2025 report-3.2%negative
Data +Jul 10, 2025
mRNA-4157 Phase 3 interim (melanoma)▸
high impact
EarningsMay 01, 2025
Q1 2025 report-9.6%negative
EarningsFeb 14, 2025
FY 2024 report+2.2%muted
EarningsJan 13, 2025
FY 2024 report-4.0%negative
EarningsNov 07, 2024
Q3 2024 report-13.5%negative
Data +Sep 10, 2024
mRNA-4157 Phase 2b melanoma 3-year follow-up▸
high impact
EarningsAug 01, 2024
Q2 2024 report-12.6%negative